NEW YORK (Reuters Health)—Patients with rheumatoid arthritis (RA) are at increased risk of serious infections, myocardial infarction (MI) and coronary heart disease (CHD), an analysis of Medicare claims data suggests. “Higher disease activity as measured by a panel of biomarkers was associated with higher rates of hospitalized infections, MI and CHD events. These findings add…
The Diagnosis: How to Advise Newly Diagnosed RA Patients
Receiving an RA diagnosis may be emotional and difficult for patients. By engaging the patient in learning about the disease and its treatment options, as well as cultivating a communicative relationship, rheumatologists can truly help a patient take control of their health…
Biosimilar SB2 May Work as Well as Infliximab for Rheumatoid Arthritis
In a 78-week study examining the interchangeability of infliximab with the biosimilar SB2, the treatments demonstrated long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis. Across all the study’s treatment groups, patients had similar treatment response rates, and the long-term clinical profile of SB2 was comparable with infliximab…
Update on ACR’s Rheumatology-Specific APM
Efforts by the ACR to develop a rheumatology-specific alternative payment model (APM) are well under way. The first draft proposal was approved by the ACR Board of Directors in November and presented to the rheumatology community during the 2017 ACR/ARHP Annual Meeting in San Diego. The ACR is pursuing the development of a rheumatology-specific APM…
Pedometers & RA: Does Increasing Physical Activity Decrease Fatigue?
Recent research examined the effectiveness of a pedometer-based intervention for managing fatigue in patients with rheumatoid arthritis (RA). During the 21-week trial, RA patients using pedometers successfully increased their physical activity, with a greater than 30% decrease in the proportion of participants classified as sedentary. Patients also decreased their reported fatigue, and some reported improvements in function, pain, depressive symptoms and disease activity levels…
Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA
In the U.S., a new formulation and an ergonomic delivery system for single doses of etanercept are now available for RA patients…
Weight Change in Early RA & the Risk of Mortality
Sparks et al set out to investigate whether weight change during the early RA period is associated with subsequent mortality and to evaluate whether there is an RA-specific effect. They investigated weight change during the early RA period, because this is the window of time during which weight change is most likely to be related to RA-specific processes. They found that severe weight loss during the early RA period was associated with a subsequent increased mortality risk both for women with and without RA…
E6011 Safe & Well Tolerated in RA Patients
E6011, an anti-fractalkine monoclonal antibody, proved promising for the treatment of rheumatoid arthritis during a 52-week clinical trial…
Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
New research demonstrates that subcutaneous tocilizumab monotherapy may preserve disease control in RA patients who have discontinued methotrexate…
Upadacitinib Promising for RA in Phase 3 Study
In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 30
- Next Page »